MSSM - ETF AI Analysis
Top Page
Morgan Stanley Pathway Small-Mid Cap Equity ETF (MSSM)
Rating:64Neutral
Price Target:―
Positive Factors
Strong Year-to-Date Performance
The ETF has delivered strong gains so far this year, indicating solid recent results for investors.
Healthy Mix of Sectors
Holdings are spread across many industries like industrials, technology, health care, and financials, which helps reduce the impact of weakness in any single sector.
Several Strong-Performing Top Holdings
Many of the largest positions, including companies in industrials and technology, have shown strong performance this year, supporting the fund’s overall returns.
Negative Factors
Higher Expense Ratio
The fund’s fees are on the higher side for an ETF, which can slightly reduce the net returns investors keep over time.
Heavy U.S. Concentration
The ETF is almost entirely invested in U.S. companies, offering very limited geographic diversification outside the United States.
Some Lagging Top Holdings
A few of the larger positions have shown weak or negative performance this year, which can drag on the fund’s overall results if the trend continues.
MSSM vs. SPDR S&P 500 ETF (SPY)
AUM695.69M
RegionNorth America
Expense Ratio0.62%
Beta0.97
IssuerMorgan Stanley
Inception DateDec 09, 2024
Dividend Yield2.74%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume13,143
30 Day Avg. Volume17,355
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
73.42Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1815
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MSSM Summary
MSSM, the Morgan Stanley Pathway Small-Mid Cap Equity ETF, focuses on smaller and mid-sized U.S. companies rather than the big household-name giants. It doesn’t track a specific index, but follows an “extended market” theme, picking a mix of industrial, technology, health care, and financial stocks. Well-known names in the fund include Dynatrace and ViaSat. Investors might consider MSSM for growth potential and diversification, since smaller companies can expand faster than large ones. However, small and mid-cap stocks can be more volatile, so the ETF’s value can go up and down more sharply with the market.
How much will it cost me?The Morgan Stanley Pathway Small-Mid Cap Equity ETF (MSSM) has an expense ratio of 0.57%, which means you’ll pay $5.70 per year for every $1,000 invested. This is higher than average because the fund is actively managed, focusing on small to mid-sized companies that require more research and oversight compared to passively managed ETFs.
What would affect this ETF?The MSSM ETF, with its focus on small to mid-cap U.S. companies, could benefit from economic growth and innovation in sectors like technology and industrials, which make up a significant portion of its holdings. However, it may face challenges from rising interest rates, which can increase borrowing costs for smaller companies, and economic slowdowns that disproportionately impact less established businesses. Regulatory changes or sector-specific disruptions could also influence the performance of its top holdings.
MSSM Top 10 Holdings
MSSM’s story is all about U.S. small and mid-cap names where a handful of rising stars are doing the heavy lifting. Software player Dynatrace has been climbing steadily, helped by strong growth and adoption, while TechnipFMC and Brinker International are also pulling the fund higher with improving fundamentals and upbeat outlooks. On the flip side, Veeco and Regal Rexnord have been lagging lately, acting as a bit of a speed bump. Overall, the fund is spread across sectors, with no single theme or stock dominating the stage.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Dynatrace | 0.85% | $5.92M | $15.94B | 14.00% | 77 Outperform | |
| Ascendis Pharma | 0.73% | $5.11M | $14.77B | 19.75% | 46 Neutral | |
| ViaSat | 0.70% | $4.88M | $10.52B | 157.95% | 56 Neutral | |
| TechnipFMC | 0.64% | $4.43M | $28.24B | 82.74% | 80 Outperform | |
| KBR | 0.63% | $4.38M | $4.48B | -27.13% | 73 Outperform | |
| IMAX | 0.54% | $3.75M | $2.89B | 65.11% | 76 Outperform | |
| Haemonetics | 0.53% | $3.69M | $4.93B | 114.23% | 70 Outperform | |
| Brinker International | 0.50% | $3.46M | $8.22B | 44.27% | 70 Neutral | |
| Avient | 0.49% | $3.42M | $3.70B | 14.85% | 63 Neutral | |
| Veeco | 0.49% | $3.41M | $2.61B | 49.63% | 70 Neutral |
MSSM Technical Analysis
Negative
―
Price Trends
59.93
Negative
59.49
Negative
56.36
Positive
Market Momentum
-0.69
Positive
34.85
Neutral
30.95
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MSSM, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 59.27, equal to the 50-day MA of 59.93, and equal to the 200-day MA of 56.36, indicating a neutral trend. The MACD of -0.69 indicates Positive momentum. The RSI at 34.85 is Neutral, neither overbought nor oversold. The STOCH value of 30.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MSSM.
MSSM Peer Comparison
Comparison Results
Performance Comparison
MSSM
Morgan Stanley Pathway Small-Mid Cap Equity ETF
57.68
7.99
16.08%
RSMC
Rockefeller U.S. Small-Mid Cap ETF
―
―
―
GRNJ
Fundstrat Granny Shots US Small- & Mid-Cap ETF
―
―
―
SMIZ
Zacks Small/Mid Cap ETF
―
―
―
RNIN
Bushido Capital US SMID Cap Equity ETF
―
―
―
ASCE
Allspring SMID Core ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents